- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03978286
Vortioxetine vs Sertraline in Mexicans
June 11, 2019 updated by: ISELA ESTHER JUAREZ-ROJOP Ph.D., Universidad Juárez Autónoma de Tabasco
Vortioxetine Versus Sertraline in Control Metabolic, Distress and Depression in Mexican Patients With Type 2 Diabetes
Depression in patients with type 2 diabetes is often undiagnosed and remains untreated, leading to poor therapy adherence and ill health-related outcomes.
The aim of study was evaluated the effect of vortioxetine versus sertraline in the treatment of depression, diabetes-related distress and control metabolic in subjects with type 2 diabetes and depression.
was included patients who were glycosylated hemoglobin ≥ 7.5%, 18 to 60 years of age and written consent .
Pharmacological treatment for depression was assigned randomly: vortioxetine (10 mg/day) or sertraline (75 mg/day) for 8 weeks.
Biochemical parameters, anthropometric measures and depression symptoms were evaluated before and at the and at the 8 weeks after antidepressant treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The assessment consisted of an extended face-to-face interview.
The patients answered a structured questionnaire used to collect: sociodemographic characteristics (gender, age, education, occupation and marital status) and clinical data (pharmacotherapy, habits, consumed of drugs, diabetes complications and comorbidities).
Depression was screened using Hamilton Depression Rating Scale score ≥ 14 (HAM-D), Center for epidemiologic studies depression scale revised in Spanish (CES-DR35), and Problem Areas in Diabetes Questionnaire (PAID-V); anthropometrics measurements were evaluated (weight, waist circumference and body mass index).
Besides, blood samples were drawn for the following biochemical parameters: fasting plasma glucose, glycated hemoglobin (HbA1c), cholesterol and triglycerides.
Patients who gave informed consent and convened inclusion criteria were attended by a psychiatrist.
The pharmacological management were randomly assigned: vortioxetine (10 mg/day) or sertraline (75 mg/day) for 8 weeks, in addition, the patients maintained their established anti-diabetic treatment (oral hypoglycemic or insulin).
The study ended at the 8th week, subjects were attended by psychiatrist and blood samples were drawn for evaluated biochemical parameters and the structured questionnaire previously described was applicated.The clinical measures and biochemical parameters were done baseline and after 8-week pharmacological treatment.
Finally the effect of both antidepressants were compared.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Individuals had to be between 18 and 85 years of age
- Clinical diagnosis of type 2 diabetes mellitus based on the American Diabetes Association criteria,
- They had to receive anti-diabetic treatment, Clinical diagnosis of major depressive episode according Association Diagnostic and Statistical Manual of Mental Disorders, five edition (DSM-V)
- Ratings scale score ≥ 14 by means of Hamilton Depression scale (HAM-D)
- Patients had to give verbal and written informed consent for this study
Exclusion Criteria:
- Neurological illness
- Psychoactive medications
- Type I diabetes
- Active suicidal ideation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vortioxetine therapy
patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist.
The pharmacological management were randomly assigned: these group of patients received vortioxetine (10 mg/day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
|
10 mg per day
Other Names:
|
Experimental: Sertraline therapy
patients who gave informed consent and met the inclusion criteria were attended by a psychiatrist.
The pharmacological management were randomly assigned: these group of patients received sertraline (75 mg / day) for 8 weeks, in addition, the patients maintained their anti-diabetic treatment (oral hypoglycemic or insulin)
|
75 mg per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of antidepressant treatment (sertraline versus vortioxetine) in remission of depression in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
Two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The assessment of depression was performed by the Hamilton Depression Rating Scale (HAM-D) validated in the Spanish version.
We used a 17-item reduced version, the range of scale was 0-50, includes the following items: psychic anxiety, somatic anxiety, gastrointestinal somatic symptoms, general somatic symptoms, hypochondriasis, and insight.
A score of 8 and above indicates depression and a high levels of anxiety symptoms.
Where 14 was the cutoff point of this scale; patients with this score were diagnosed with major depression and included in the study.
Depression was screened using HAM-D at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in severity of depression in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
Two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The severity of depression was measured with the center for epidemiologic studies depression scale revised in Spanish (CES-DR35).
Previous studies in a Mexican population reported a Cronbach α score of 0.9.
This questionnaire consists of 35 items, the range of scale was 0-140, among them are: depressed mood, anhedonia, appetite, sleep problem, psychomotor retardation, fatigue, guilt/conscience, thinking, suicidal ideation and social.
A score of 16 and above indicates clinically significant symptoms of major depression episode and the severity of depression.
Depression was screened using CES-DR35 at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in treatment of diabetes related stress in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
Two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
Diabetes related stress was screened using 5-item Problem Areas in Diabetes Scale (PAID-5).
The scale gives a total score from 0 to 20.
A score of 8 and above indicates a high level of diabetes-related distress.
Diabetes related stress was screened using PAID-5 at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in fasting plasma glucose level in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
Two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The glycemic variable was measured by fasting plasma glucose level in mg/dl.
at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in glycemic control in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
Two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The glycemic variable was measured by glycosylated hemoglobin A 1c in percentage at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in cholesterol control in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
Two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The metabolic variable was measured by cholesterol in mg/dL at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in triglycerides control in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
Two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The metabolic variable was measured by triglycerides in mg/dL at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of antidepressant treatment (sertraline versus vortioxetine) in weigh in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The anthropometric variables were evaluated in the weight in kilograms at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in waist circumference in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The anthropometric variables were evaluated in waist circumference in centimeters at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Effect of antidepressant treatment (sertraline versus vortioxetine) in anthropometric variables in depressed type 2 diabetic patients.
Time Frame: 8 weeks
|
two groups of depressed type 2 diabetic patients were involve in the study: one group received sertraline and the second vortioxetine.
The anthropometric variables were evaluated, weight and height will be combined to report BMI in kg/m^2 at the beginning of the study and at 8 weeks of treatment.
Finally the effect of both antidepressant were compared.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Isela Juarez Rojop, Ph.D, Universidad Juárez Autónoma de Tabasco
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Petrak F, Herpertz S, Albus C, Hermanns N, Hiemke C, Hiller W, Kronfeld K, Kruse J, Kulzer B, Ruckes C, Zahn D, Muller MJ. Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study: A Randomized Controlled Multicenter Trial. Diabetes Care. 2015 May;38(5):767-75. doi: 10.2337/dc14-1599. Epub 2015 Feb 17.
- Rachdi C, Damak R, Fekih Romdhane F, Ouertani H, Cheour M. Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients. Prim Care Diabetes. 2019 Feb;13(1):57-62. doi: 10.1016/j.pcd.2018.09.003. Epub 2018 Oct 2.
- D'Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015 Jan;40(1):36-40.
- Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2019 Jun;24(3):338-347. doi: 10.1017/S1092852918000913. Epub 2018 May 24.
- Kesim M, Tiryaki A, Kadioglu M, Muci E, Kalyoncu NI, Yaris E. The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: A prospective clinical trial on depressive patients. J Res Med Sci. 2011 Dec;16(12):1525-31.
- Llorca PM, Lancon C, Brignone M, Rive B, Salah S, Ereshefsky L, Francois C. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Curr Med Res Opin. 2014 Dec;30(12):2589-606. doi: 10.1185/03007995.2014.969566. Epub 2014 Oct 10.
- Petrak F, Baumeister H, Skinner TC, Brown A, Holt RIG. Depression and diabetes: treatment and health-care delivery. Lancet Diabetes Endocrinol. 2015 Jun;3(6):472-485. doi: 10.1016/S2213-8587(15)00045-5. Epub 2015 May 17.
- Rosenblat JD, Kakar R, McIntyre RS. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Int J Neuropsychopharmacol. 2015 Jul 25;19(2):pyv082. doi: 10.1093/ijnp/pyv082. Erratum In: Int J Neuropsychopharmacol. 2016 Apr 27;:
- Tovilla-Zarate CA, Perez-Mandujano A, Ramirez-Gonzalez IR, Fresan A, Suarez-Mendez S, Martinez-Villasenor E, Rodriguez-Sanchez E, Villar-Soto M, Lopez-Narvaez ML, Gonzalez-Castro TB, Ble-Castillo JL, Juarez-Rojop IE. Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes. Ann Transl Med. 2019 Nov;7(22):656. doi: 10.21037/atm.2019.10.56.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 30, 2016
Primary Completion (Actual)
June 30, 2017
Study Completion (Actual)
June 30, 2018
Study Registration Dates
First Submitted
March 18, 2019
First Submitted That Met QC Criteria
June 4, 2019
First Posted (Actual)
June 7, 2019
Study Record Updates
Last Update Posted (Actual)
June 13, 2019
Last Update Submitted That Met QC Criteria
June 11, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Glucose Metabolism Disorders
- Metabolic Diseases
- Mood Disorders
- Endocrine System Diseases
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Sertraline
- Vortioxetine
Other Study ID Numbers
- 00228/16.
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
the information will be available when contacting the correspondence author
IPD Sharing Time Frame
Once the article is published, information about the study will be available for a period of 3 years.
IPD Sharing Access Criteria
direct contact with the correspondence author
IPD Sharing Supporting Information Type
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on Vortioxetine
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompletedPharmacokineticsChina
-
H. Lundbeck A/SCompleted
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
H. Lundbeck A/SCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedSingle Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating TabletsMajor Depressive Disorder (MDD)India
-
H. Lundbeck A/STakedaCompletedDepressive Disorder, MajorFinland, Estonia
-
H. Lundbeck A/SCompletedMajor Depressive DisorderBulgaria, Estonia, Latvia
-
Rush University Medical CenterElMindA Ltd; Takeda Pharmaceuticals North America, Inc.CompletedMajor Depressive DisorderUnited States
-
Lundbeck Canada Inc.CompletedMajor Depressive DisorderCanada